Quantcast
Last updated on April 21, 2014 at 8:43 EDT

Physicians Estimate That If Approved, Ceftobiprole Will Steal Nearly a Third of Zyvox’s Patient Share in the Treatment of Nosocomial Pneumonia

September 22, 2008

MALVERN, Penn. and WALTHAM, Mass., Sept. 22 /PRNewswire/ — Arlington Medical Resources (AMR) and Decision Resources find that over 80 percent of surveyed hospital physicians estimate that if approved, Basilea/Johnson & Johnson’s ceftobiprole will steal, on average, nearly a third of Pfizer’s Zyvox patient share in the treatment of nosocomial pneumonia. In addition, several product profiles that are analogous to ceftobiprole and other antibiotics were presented to physicians to see how they would compete within the nosocomial pneumonia drug market. The new report entitled Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia found that the ceftobiprole analogue profile is well positioned to compete in this drug market.

“We presented several antibiotic product profiles to physicians we surveyed that are analogous to ceftobiprole, Forest’s ceftaroline in combination with a beta-lactamase inhibitor and Theravance/Astellas’s telavancin to assess the potential positioning of these agents in the future nosocomial pneumonia market,” states John Lebbos, M.D., Vice President of Infectious Diseases at Decision Resources. “Physicians were highly receptive to these profiles — in fact, 67 percent of physicians indicated that the ceftobiprole analogue profile is well positioned to compete in the large empiric, first-line therapy market for nosocomial pneumonia.”

The report also finds that hospital prescribing patterns are mainly driven by an institution’s infectious disease consults and by guidelines presented by the American Thoracic Society (ATS) and the Infectious Disease Society of America (IDSA). A hospital’s protocol and local guidelines play the next important role. Therefore, key stakeholders such as hospital infectious disease specialists and clinicians developing an institution’s guidelines typically have broad influence on prescribing well beyond their own patients.

AMR and Decision Resources’ new Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR’s comprehensive and highly detailed clinical data in conjunction with Decision Resources’ disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians’ product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

   2008 Hospital Anti-Infective Insight Series reports include:    -- Hospital Anti-Infective Insight Series: Nosocomial Pneumonia   -- Hospital Anti-infective Insight Series: Skin & Soft Tissue Infections   -- Hospital Anti-Infective Insight Series: U.S. Antibiotic Usage Patterns      and Drivers in the ICU Setting     About AMR  

AMR (http://www.amr-data.com/) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits.

About Decision Resources

Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com/.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Natalia Morales             Elizabeth Marshall   Decision Resources          Decision Resources, Inc.   781-296-2691                781-296-2563   nmorales@dresources.com     emarshall@dresources.com  

Arlington Medical Resources; Decision Resources

CONTACT: Natalia Morales of Decision Resources, +1-781-296-2691,nmorales@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com

Web site: http://www.decisionresources.com/http://www.decisionresourcesinc.com/http://www.amr-data.com/